Antibiotic Therapy for Surgical Site Infections
Introduction to Antibiotic Selection
- The World Health Organization (WHO) recommends appropriate antibiotic therapy for surgical site infections following surgery of the trunk, with gram-positive coverage being essential, and considers MRSA coverage when indicated 1
Treatment of Skin Infections
- Dalbavancin is recommended as an effective intravenous option for treating Cutibacterium skin infections, particularly in cases where standard therapies have failed or when compliance with daily medication is a concern, with a treatment duration of 7-14 days, as recommended by the World Journal of Emergency Surgery guidelines 2
- The FDA approves dalbavancin for acute bacterial skin and skin structure infections (ABSSSI) with two dosing regimens: a two-dose regimen of 1000 mg IV on day 1, followed by 500 mg IV on day 8, and a single-dose regimen of 1500 mg IV, with equivalent efficacy in clinical trials, as recommended by the World Journal of Emergency Surgery and the FDA 2, 3
- Alternative therapies for ABSSSI include daptomycin, IV linezolid, IV ceftaroline, IV vancomycin, IV tigecycline, and IV tedizolid, as listed by the World Journal of Emergency Surgery, and beta-lactams are considered first-line therapy for implant-related Cutibacterium acnes infections, with benzyl penicillin (IV) followed by oral amoxicillin being a recommended option, as suggested by the American Society of Microbiology and the Infectious Diseases Society of America 2, 4
- Clindamycin, fluoroquinolones, or doxycycline may be considered as alternative options based on susceptibility patterns, and rifampicin may have efficacy against Cutibacterium infections based on animal models, but its clinical value lacks prospective, randomized controlled studies 4, 5
- Surgical debridement alongside antibiotic therapy is often necessary for deep-seated or implant-related Cutibacterium infections, and the decision for surgical intervention should be made early in the treatment course for optimal outcomes, as recommended by the Infectious Diseases Society of America and the World Journal of Emergency Surgery guidelines 2, 4
Safety and Efficacy
- Dalbavancin demonstrates a favorable safety profile with lower nephrotoxicity rates compared to vancomycin, and is particularly effective against MRSA infections with clinical success rates of 92.9% (single-dose) and 95.3% (two-dose) in patients with MRSA at baseline, as recommended by the World Journal of Emergency Surgery 2
- However, there is potential for development of resistance with inappropriate use of dalbavancin against Cutibacterium species, and cross-resistance between dalbavancin, daptomycin, and vancomycin has been reported, and cost considerations may limit the use of dalbavancin compared to other effective antibiotics 6
Treatment Considerations
- The Infectious Diseases Society of America recommends considering the site and severity of infection, evaluating if the infection is implant-related, and assessing antimicrobial susceptibility patterns when treating Cutibacterium infections 4
- Dose adjustments are necessary for patients with severe renal impairment (CrCl < 30 mL/min), and IV to oral switch should occur when clinical stability is achieved, as recommended by the World Journal of Emergency Surgery 2